Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has announced that new findings from ongoing Pradaxa (dabigatran etexilate) research will be presented during the American College of Cardiology’s 63rd Annual Scientific Session (ACC.14) in Washington, USA, 29 – 31 March 2014. The data form part of Boehringer Ingelheim’s ongoing commitment to scientific innovation and advancing patient care.

Data from three separate company-sponsored Pradaxa-related studies will be announced during the congress. The presentations will cover subgroup results from the pivotal RE-LY trial, evaluating the use of Pradaxa compared to warfarin in patients with atrial fibrillation and valvular heart disease. An oral presentation will highlight new data from pre-clinical research into an investigational antidote for Pradaxa. Furthermore, first data from GLORIA-AF, one of the largest worldwide atrial fibrillation registries will be announced. The GLORIA-AF registry programme is expected to provide meaningful knowledge on the global role and use of antithrombotic treatments in protecting patients with atrial fibrillation against the devastating effects of stroke.

“The American College of Cardiology’s 63rd Annual Scientific Session provides a key opportunity to share new data with physicians to increase understanding of the latest developments in the field of anticoagulation,” said professor Klaus Dugi, chief medical officer, Boehringer Ingelheim.

“At Boehringer Ingelheim we are proud of our commitment to driving research and innovation in the cardiovascular area. We hope this new data will support ongoing efforts to improve patient outcomes, especially in the area of stroke prevention in atrial fibrillation.”

Details of the Pradaxa abstracts to be presented during the American College of Cardiology’s 63rd Annual Scientific Session can be found within the Scientific Programme.

Clinical experience of Pradaxa (dabigatran etexilate) exceeds that of all other novel oral anticoagulants, equating to over 2.7 million patient-years in all licensed indications worldwide. Currently approved indications for Pradaxa are:6 Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) and a risk factor for stroke Primary prevention of venous thromboembolic events in patients undergoing elective total hip replacement surgery Primary prevention of venous thromboembolic events in patients undergoing elective total knee replacement surgery.